Learn more about BPC-157 therapy for men in Anaheim. Click here to learn more about CJC-1295 therapy for women in Anaheim. Learn more about CJC-1295 therapy for men in Anaheim. Click here to learn more about GHRP-6 and GHRP-2 therapy for women in Anaheim.
By week 6–8, you may start noticing actual body composition shifts. Body changes come later — give it at least 3 months before evaluating whether it's working for body recomposition. If sleep is improving, that's a real signal the peptide is working. The most commonly reported effect in the first month is improved sleep quality — often the first thing users notice. People who quit after 4–6 weeks because "nothing happened" are the ones who miss the point of this peptide entirely.
The study measured multiple serum hormone values throughout the treatment period while also assessing changes in the GH release waveform induced by GHRH vs. GHRP-2. These results highlight that, compared to the short-term treatment in the Vittone study, longer term treatment with sermorelin results in increases in GH and IGF-1 in addition to changes in body composition seen with increased lean body mass. For men, no changes in testosterone levels were observed but a significant increase in insulin sensitivity was noted along with improvements in wellbeing and libido. IGF-1 levels rose significantly by 2 weeks of treatment and remained elevated until 12 weeks before declining at 16 weeks. Ten women and nine men between 55 and 71 years old were administered 4 weeks of nightly subcutaneous placebo followed by 16 weeks of 10 µg/kg of sermorelin.
By mimicking ghrelin, ipamorelin selectively binds the same GHSR-1a receptor as GHRP-2, GHRP-6, and ibutamoren (55,56). These findings demonstrate that ibutamoren treatment can increase GH and IGF-1 levels for up to 2 years. The group that started ibutamoren during the second year saw the same changes while the group that switched to placebo in the second year saw a reversal of the changes induced by ibutamoren treatment in the first year. The original ibutamoren treatment group was separated into either a placebo or continued ibutamoren treatment group. Ibutamoren treatment did not affect FSH and LH levels, but did lead to decreased total testosterone levels with conserved free testosterone levels. The ibutamoren treatment group experienced a significant weight gain of 2.7 kg at 8 weeks, which decreased to a nonsignificant 1.8 kg weight gain 1 week after the end of treatment. Paralleling the Chapman et al. study, ibutamoren led to an elevation in serum prolactin at 2 and 8 weeks but no significant changes were observed in serum or urine cortisol.
Based on the literature, current indications for the use of GHS’s include treatment of wasting and as treatment for GH deficiency. Elevations in IGF-1 levels in patients on GHS’s lead to increased insulin insensitivity, which can result in blood glucose elevations. In this trial, increased FFM did not result in increased strength, and abdominal visceral fat content was not affected(58). This trial did not show changes in visceral or abdominal fat mass when these parameters were examined(56). These studies, however, are limited by one-time administration of drug and a lack of somatic endpoints that assess changes in body composition over time. These results demonstrate that obesity blunts but does not eliminate the effect of GHRP on GH secretion, and that the synergistic effect of combination therapy with GHRH may be useful in restoring the GH axis in obese individuals. However, in a follow-up study, the responses of 12 obese and 8 non-obese subjects to a combination of GHRH and GHRP-6 (100mcg each, intravenously), were compared, with a lower GH response observed in obese than in non-obese patients(53).

Gender: Female

Social links